Fig. 1.

RIVER study Flow-Chart. All patients with PAH (PATENT-1 and 2, PATENTplus) or CTEPH (CHEST-1 and 2, Early Access Study) randomized into one of the trials (i.e. for whom study medication had been assigned and a package had been opened) and who had at least once been administered study medication were eligible for the study, if echocardiography had been routinely performed at baseline and at least once during the course of the trial